Survey Asks Why Some Ovarian Cancer Patients Choose Maintenance Therapy
Many patients who completed the survey felt maintenance therapy would help them buy time.
No Benefit in Increased Surveillance After Lung Cancer Surgery
Expanding surveillance after surgery from chest X-ray to follow-up with PET-CT scan did not improve overall survival (OS), researchers reported during the 2017 ESMO Congress.
Keytruda Bests Chemotherapy in Overall Survival Rates for Bladder Cancer
Keytruda (pembrolizumab) produced better overall survival (OS) rates than chemotherapy for patients with recurrent, advanced urothelial carcinoma.
PD-1 Blockades Show Potential in Sarcoma
Patients with certain types of sarcoma may benefit from PD-1 blockades, according to a recent study.
Ribociclib Has Similar Benefits for Elderly Patients With Breast Cancer
A recent trial showed that ribociclib had the similar benefits for elderly patients with breast cancer as it did for younger patients.
A New Standard of Care for Advanced Urothelial Carcinoma
After results from a phase 3 trial showed that Keytruda improved overall survival, it may become the next standard of care for patients with advanced urothelial carcinoma.
Anti PD-L1 Agent Shows Durable Response in Lung Cancer
According to results from a recent trial, patients with heavily pretreated lung cancer showed a durable response and clinical benefit with durvalumab.
New Agent Improves Intracranial PFS for Lung Cancer and Brain Metastases
Icotinib greatly improved intracranial progression-free survival for patients with lung cancer who have brain metastases, according to a recent study.
Immunotherapy Agent May Have Early Survival Risk in Lung Cancer
While Opdivo showed improved overall survival, there may be a survival risk within the first few months of taking it, according to recently presented data.
Anti-PD-L1 Agent Is Promising for Frontline Lung Cancer Treatment
Early results showed that avelumab may be a promising option for the treatment of patients with advanced lung cancer.
Trial Data May Change Standard Second-Line Treatment of Liver Cancer
After doing well in a phase 3 trial, Stivarga showed the potential to shift the treatment paradigm for previously treated liver cancer.
Encouraging Phase 2 Trial Data Seen With Immunotherapy in Metastatic Anal Cancer
Opdivo may be a promising treatment option for patients with squamous cell carcinoma of the anal canal.
Immunotherapy Research Continues in Bladder Cancer
The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.
